Logo

Inhibrx, Inc.

INBX

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of… read more

Healthcare

Biotechnology

3 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$34.10

Price

+1.25%

$0.42

Market Cap

$493.939m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$1.400m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$163.694m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$10.80

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$68.559m

$212.118m

Assets

$143.559m

Liabilities

$7.510m

Debt
Debt to Assets

3.5%

-

Debt to EBITDA
Free Cash Flow

-$140.133m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases